<p>在過去三個月中，6 位分析師對 Cormedix（納斯達克：CRMD）發佈了評級，提供了從看漲到看跌的多樣化觀點。</p>
<p>總結他們最近的評估，下面的表格展示了過去 30 天情緒的變化，並與前幾個月進行了比較。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>提供更深入的見解，分析師設定了 12 個月的價格目標，顯示出平均目標為$13.83，最高預估為$15.00，最低預估為$13.00。當前平均價格較之前的平均目標$16.33 下降了 15.31%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770814843_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="價格目標圖表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770814843_0.png"/></p>
<h2>解讀分析師評級：詳細分析</h2>
<p>通過對最近分析師行動的全面分析，描繪了 Cormedix 在金融專家中的認知。下面的總結概述了關鍵分析師、他們最近的評估以及對評級和價格目標的調整。</p>
<table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>維持</td>
<td>買入</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Brandon Folkes</td>
<td>HC Wainwright &amp; Co.</td>
<td>下調</td>
<td>買入</td>
<td>$13.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>下調</td>
<td>超過市場</td>
<td>$13.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>下調</td>
<td>買入</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>維持</td>
<td>買入</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>維持</td>
<td>買入</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<h3>關鍵見解：</h3>
<ul>
<li><strong>採取的行動：</strong> 分析師根據不斷變化的市場條件和公司表現頻繁更新他們的建議。無論是'維持'、'上調'還是'下調'他們的立場，反映了他們對 Cormedix 相關最新發展的反應。這些信息提供了分析師對公司當前狀態的快照。</li>
<li><strong>評級：</strong> 提供全面分析，分析師提供定性評估，從'超過市場'到'低於市場'。這些評級反映了對 Cormedix 相對於更廣泛市場表現的預期。</li>
<li><strong>價格目標：</strong> 分析師在價格目標的調整中進行導航，提供對 Cormedix 未來價值的估計。比較當前和之前的目標提供了分析師不斷變化的預期的見解。</li>
</ul>
<p>通過這些分析師評估與其他財務指標的結合，可以幫助全面理解 Cormedix 的市場地位。保持信息靈通，並通過我們的評級表做出數據驅動的決策。</p>
<p>隨時瞭解 Cormedix 的分析師評級。</p>
<p>如果您對跟蹤小型股新聞和表現感興趣，您可以從這裏開始跟蹤。</p>
<h2>更好地瞭解 Cormedix</h2>
<p>Cormedix Inc 是一家生物製藥公司，專注於開發和商業化針對危及生命的疾病和狀況的治療產品。該公司專注於在美國及其他關鍵市場商業化其產品 DefenCath。該集團目前在一個單一的細分市場運營，藥品產品，位於一個地理位置，即美國。</p>
<h3>關鍵指標：Cormedix 的財務健康</h3>
<p><strong>市值：</strong> 與行業平均水平相比，公司的市值較小，面臨獨特的挑戰。</p>
<p><strong>收入增長：</strong> Cormedix 在過去三個月中表現出積極的結果。截至 2025 年 9 月 30 日，該公司實現了約 <strong>810.22%</strong> 的強勁收入增長率。這表明公司的收入大幅增加。與競爭對手相比，該公司的增長率高於醫療保健行業的平均水平。</p>
<p><strong>淨利潤率：</strong> Cormedix 的淨利潤率超越行業基準，達到 <strong>104.11%</strong>。這表明其成本管理高效，財務健康狀況良好。</p>
<p><strong>股本回報率（ROE）：</strong> Cormedix 的財務實力體現在其卓越的 ROE 上，超過行業平均水平。該公司的 ROE 達到 <strong>36.51%</strong>，展示了其對股本資本的高效利用和強勁的財務健康。</p>
<p><strong>資產回報率（ROA）：</strong> Cormedix 的 ROA 表現突出，超過行業平均水平。該公司的 ROA 達到 <strong>21.64%</strong>，展示了其資產的有效利用和強勁的財務表現。</p>
<p><strong>債務管理：</strong> Cormedix 的債務與股本比率顯著高於行業平均水平，達到 <strong>0.4</strong>。這表明對借款資金的依賴較重，增加了財務槓桿的擔憂。</p>
<h2>分析師評級是如何確定的？</h2>
<p>銀行和金融系統的專家，分析師專注於特定股票或定義行業的報告。他們的全面研究包括參加公司電話會議和會議，分析財務報表，並與內部人士互動，以生成所謂的股票分析師評級。通常，分析師每季度評估和評級每隻股票一次。</p>
<p>一些分析師還提供有助於預測收益、收入和增長估計等指標的預測，以進一步指導對特定股票的操作。需要記住的是，儘管股票和行業分析師是專家，但他們也是人，只能將自己的信念預測給交易者。</p>
<p>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</p>

CRMD

<p>在過去三個月中，六位分析師對 Cormedix（NASDAQ:CRMD）進行了評級，顯示出從看漲到看跌的情緒混合。12 個月的平均目標價為 13.83 美元，低於 16.33 美元，最高為 15.00 美元，最低為 13.00 美元。分析師們調整了他們的評級，有些維持不變，有些則下調了目標價。Cormedix 顯示出約 810.22% 的顯著收入增長和 104.11% 的淨利潤率。然而，其債務與股本比率高於行業平均水平，表明其對借款資金的依賴</p>

<p>In the last three months, 6 analysts have published ratings on Cormedix (NASDAQ: CRMD), offering a diverse range of perspectives from bullish to bearish.</p>
<div class="lb-trans"><p>在過去三個月中，6 位分析師對 Cormedix（納斯達克：CRMD）發佈了評級，提供了從看漲到看跌的多樣化觀點。</p>
</div><p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<div class="lb-trans"><p>總結他們最近的評估，下面的表格展示了過去 30 天情緒的變化，並與前幾個月進行了比較。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $13.83, along with a high estimate of $15.00 and a low estimate of $13.00. Highlighting a 15.31% decrease, the current average has fallen from the previous average price target of $16.33.</p>
<div class="lb-trans"><p>提供更深入的見解，分析師設定了 12 個月的價格目標，顯示出平均目標為$13.83，最高預估為$15.00，最低預估為$13.00。當前平均價格較之前的平均目標$16.33 下降了 15.31%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770814843_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2026/1770814843_0.png"/></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<div class="lb-trans"><h2>解讀分析師評級：詳細分析</h2>
</div><p>A clear picture of Cormedix's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通過對最近分析師行動的全面分析，描繪了 Cormedix 在金融專家中的認知。下面的總結概述了關鍵分析師、他們最近的評估以及對評級和價格目標的調整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Brandon Folkes</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$13.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>維持</td>
<td>買入</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Brandon Folkes</td>
<td>HC Wainwright &amp; Co.</td>
<td>下調</td>
<td>買入</td>
<td>$13.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>下調</td>
<td>超過市場</td>
<td>$13.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Serge Belanger</td>
<td>Needham</td>
<td>下調</td>
<td>買入</td>
<td>$15.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>維持</td>
<td>買入</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jason Kolbert</td>
<td>D. Boral Capital</td>
<td>維持</td>
<td>買入</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>關鍵見解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cormedix. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Cormedix compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Cormedix's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>採取的行動：</strong> 分析師根據不斷變化的市場條件和公司表現頻繁更新他們的建議。無論是'維持'、'上調'還是'下調'他們的立場，反映了他們對 Cormedix 相關最新發展的反應。這些信息提供了分析師對公司當前狀態的快照。</li>
<li><strong>評級：</strong> 提供全面分析，分析師提供定性評估，從'超過市場'到'低於市場'。這些評級反映了對 Cormedix 相對於更廣泛市場表現的預期。</li>
<li><strong>價格目標：</strong> 分析師在價格目標的調整中進行導航，提供對 Cormedix 未來價值的估計。比較當前和之前的目標提供了分析師不斷變化的預期的見解。</li>
</ul>
</div><p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Cormedix's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<div class="lb-trans"><p>通過這些分析師評估與其他財務指標的結合，可以幫助全面理解 Cormedix 的市場地位。保持信息靈通，並通過我們的評級表做出數據驅動的決策。</p>
</div><p>Stay up to date on Cormedix analyst ratings.</p>
<div class="lb-trans"><p>隨時瞭解 Cormedix 的分析師評級。</p>
</div><p>If you are interested in following small-cap stock news and performance you can start by tracking it here.</p>
<div class="lb-trans"><p>如果您對跟蹤小型股新聞和表現感興趣，您可以從這裏開始跟蹤。</p>
</div><h2>Get to Know Cormedix Better</h2>
<div class="lb-trans"><h2>更好地瞭解 Cormedix</h2>
</div><p>Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.</p>
<div class="lb-trans"><p>Cormedix Inc 是一家生物製藥公司，專注於開發和商業化針對危及生命的疾病和狀況的治療產品。該公司專注於在美國及其他關鍵市場商業化其產品 DefenCath。該集團目前在一個單一的細分市場運營，藥品產品，位於一個地理位置，即美國。</p>
</div><h3>Key Indicators: Cormedix's Financial Health</h3>
<div class="lb-trans"><h3>關鍵指標：Cormedix 的財務健康</h3>
</div><p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<div class="lb-trans"><p><strong>市值：</strong> 與行業平均水平相比，公司的市值較小，面臨獨特的挑戰。</p>
</div><p><strong>Revenue Growth:</strong> Cormedix displayed positive results in 3M. As of 30 September, 2025, the company achieved a solid revenue growth rate of approximately <strong>810.22%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增長：</strong> Cormedix 在過去三個月中表現出積極的結果。截至 2025 年 9 月 30 日，該公司實現了約 <strong>810.22%</strong> 的強勁收入增長率。這表明公司的收入大幅增加。與競爭對手相比，該公司的增長率高於醫療保健行業的平均水平。</p>
</div><p><strong>Net Margin:</strong> Cormedix's net margin excels beyond industry benchmarks, reaching <strong>104.11%</strong>. This signifies efficient cost management and strong financial health.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> Cormedix 的淨利潤率超越行業基準，達到 <strong>104.11%</strong>。這表明其成本管理高效，財務健康狀況良好。</p>
</div><p><strong>Return on Equity (ROE):</strong> Cormedix's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>36.51%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> Cormedix 的財務實力體現在其卓越的 ROE 上，超過行業平均水平。該公司的 ROE 達到 <strong>36.51%</strong>，展示了其對股本資本的高效利用和強勁的財務健康。</p>
</div><p><strong>Return on Assets (ROA):</strong> Cormedix's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>21.64%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> Cormedix 的 ROA 表現突出，超過行業平均水平。該公司的 ROA 達到 <strong>21.64%</strong>，展示了其資產的有效利用和強勁的財務表現。</p>
</div><p><strong>Debt Management:</strong> Cormedix's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.4</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> Cormedix 的債務與股本比率顯著高於行業平均水平，達到 <strong>0.4</strong>。這表明對借款資金的依賴較重，增加了財務槓桿的擔憂。</p>
</div><h2>How Are Analyst Ratings Determined?</h2>
<div class="lb-trans"><h2>分析師評級是如何確定的？</h2>
</div><p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<div class="lb-trans"><p>銀行和金融系統的專家，分析師專注於特定股票或定義行業的報告。他們的全面研究包括參加公司電話會議和會議，分析財務報表，並與內部人士互動，以生成所謂的股票分析師評級。通常，分析師每季度評估和評級每隻股票一次。</p>
</div><p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<div class="lb-trans"><p>一些分析師還提供有助於預測收益、收入和增長估計等指標的預測，以進一步指導對特定股票的操作。需要記住的是，儘管股票和行業分析師是專家，但他們也是人，只能將自己的信念預測給交易者。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自動內容引擎生成，並經過編輯審核。</p>
</div>

分析師對 Cormedix 未來的預期